Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market US$ 3.5 Billion by 2021

The global idiopathic pulmonary fibrosis treatment market expected to reach US$ 3.5 billion by 2021, growing at CAGR 14.4% over the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments.

Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type - Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050)
and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/

The global idiopathic pulmonary fibrosis treatment market research report provides market size (Revenue USD Million 2014 to 2021), patient numbers by disease severity and by country (U.S., Japan, U.K. Germany, France, Italy, Spain, 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global idiopathic pulmonary fibrosis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global idiopathic pulmonary fibrosis treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.

The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments. Major players operating in the global idiopathic pulmonary fibrosis treatment market and profiled in this report include Aeolus Pharmaceuticals, Baxter International, Biogen, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Gilead Sciences, Inventiva Pharma, MediciNova, Inc., Merck & Co. (Afferent Pharmaceuticals, Inc.), Promedior, Inc., Prometheus Laboratories, Inc., and Shionogi & Company.

1. Treatment Type
1.1. Pharmacological Treatment - Drug (Brand)
1.1.1. Pirfenidone (Esbriet)
1.1.2. Nintedanib (Ofev)
1.1.3. Generic Pirfenidone
1.2. Non-pharmacological Treatment
1.2.1. Oxygen Therapy
1.2.2. Pulmonary Rehabilitation
1.2.3. Mechanical Ventilation
1.2.4. Lung Transplantation
1.2.5. Other Non-Pharmacological Treatment

2. Patients (Disease Severity)
2.1. Mild
2.2. Moderate
2.3. Severe

3. Pipeline Analysis
3.1. AEOL-10150
3.2. Lebrikizumab
3.3. Tipelukast
3.4. Tralokinumab
3.5. FG-3019
3.6. Simtuzumab
3.7. BMS-986020
3.8. AF-219
3.9. SAR156597
3.10. BG00011
3.11. PRM-151
3.12. PBI-4050

4. Geography
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC
4.5. Rest of the World

5. Company Profiles
5.1. Aeolus Pharmaceuticals
5.2. Baxter International
5.3. Biogen, Inc.
5.4. Boehringer Ingelheim
5.5. F. Hoffmann-La Roche
5.6. FibroGen, Inc.
5.7. Gilead Sciences
5.8. Inventiva Pharma
5.9. MediciNova, Inc.
5.10. Merck & Co. (Afferent Pharmaceuticals, Inc.)
5.11. Promedior, Inc.
5.12. Prometheus Laboratories, Inc.
5.13. Shionogi & Company

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com

This release was published on openPR.